Status:
COMPLETED
Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
AstraZeneca
Conditions:
Bone Metastases
Breast Cancer
Eligibility:
FEMALE
Brief Summary
Bone is the most common site of distant breast cancer recurrence, and 65-75% of women with advanced breast cancer will develop bone metastases during the course of their disease. The most pressing pro...
Detailed Description
Bone is the most common site of distant breast cancer recurrence, and 65-75% of women with advanced breast cancer will develop bone metastases during the course of their disease. Bone metastases can s...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- patients with metastatic breast cancer treated at Princess Margaret Hospital
Exclusion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01144481
Start Date
February 1 2009
End Date
April 1 2013
Last Update
January 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network
Toronto, Ontario, Canada, M5G 2C4